FORWARD FEATURES CALENDAR

Share this article?

NEWSLETTER

Like this article?

Sign up to our free newsletter

HealthMyne raises USD4.5m in Series A VC financing

HealthMyne has raised USD4.5m in a Series A investment round led by venture capital firms – Venture Investors and 4490 Ventures. 

Additional participants include HealthX Ventures and several prominent angel investors.

HealthMyne was founded in 2013 by a group of healthcare industry entrepreneurs. Their prior start-up experiences include TomoTherapy, Geometrics, and UltraVisual. 

According to Rock Mackie, a HealthMyne founder: “There’s been a lot of attention directed toward personalized health and evidence-based medicine, but we feel confident that we are in the best position to turn that vision into reality for clinical imaging and oncology. Importantly, the first step began with the formation of our truly industry-leading team.”

HealthMyne is focused on providing novel search, analytics, and imaging (SAI) solutions to cancer care providers. Its innovative SAI technology provides physicians with enhanced tumour image manipulation, as well as EHR and image repository search capabilities for diagnosing and treating similar cases. The first product, launching later this year, will help clinicians better detect and diagnose lung nodules as part of a comprehensive low dose CT lung screening program.

“In order to move to a whole new level of patient care, healthcare enterprises must find a way to unlock the power, and resulting impact, contained within their big data – and there is no bigger sea of digital data than that contained in clinical imaging,” says Scott Button, Managing Director at Venture Investors.

“Obviously, there is significant investment occurring in healthcare informatics, especially within the data analytics segment,” says Greg Robinson, Managing Director at 4490 Ventures. “However, what makes HealthMyne so exciting is their unique position and proven expertise relative to clinical imaging analysis. Although this is a challenging area, it offers tremendous economic and clinical benefit opportunities.”

The funds will be used to expand and accelerate HealthMyne’s product development, regulatory, and commercialization efforts.

Like this article? Sign up to our free newsletter

FEATURED

MOST RECENT

FURTHER READING